Capricor Therapeutics Publishes Results of CAP-1002 in P-II (HOPE-2) Trial for Late-Stage Duchenne Muscular Dystrophy in The Lancet
Shots:
- The P-II (HOPE-2) trial evaluates CAP-1002 (IV) vs PBO in 20 boys and young men with advanced stages of DMD & are in later stages of the disease’s progression at nine sites across the US
- The results showed that 80% of patients were non-ambulant, and all patients were on a stable regimen of steroids while demographic and baseline characteristics were similar b/w two treatment groups
- Additionally, the final data showed that young men experienced improvements in skeletal and cardiac measurements after receiving 4 doses of CAP-1002 @1yr., weakness in upper limb function & cardiac function deterioration. The therapy was safe and well-tolerated with no serious safety signals
Ref: Globe Newswire | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
